Picture of Edgewise Therapeutics logo

EWTX — Edgewise Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapMomentum Trap

Edgewise Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

* Edgewise Therapeutics Inc  EWTX.OQ  reported a quarterly
adjusted loss of 33 cents​​ per share for the quarter ended in
March, higher than the same quarter last year, when the company
reported EPS of -36 cents.  The mean expectation of six analysts
for the quarter was for a loss of 39 cents per share. Wall
Street expected results to range from -49 cents to -28 cents per
share.
    * Reported revenue was zero​; analysts expected zero. 
    * Edgewise Therapeutics Inc's reported EPS for the quarter
was a
loss of 33 cents​.
    * The company reported a quarterly loss of $28.53 million.
    * Edgewise Therapeutics Inc shares had risen by 14.5% this
quarter and gained 91.0% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 12.2%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Edgewise
Therapeutics Inc is $29.00 
This summary was machine generated from LSEG data May 9 at 02:14
p.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.39          -0.33          Beat
 Dec. 31 2023      -0.43          -0.47          Missed
 Sep. 30 2023      -0.40          -0.41          Missed
 Jun. 30 2023      -0.40          -0.34          Beat

Recent news on Edgewise Therapeutics

See all news